XIAP (E3 ubiquitin-protein ligase XIAP) variants and mutations
XIAP (also known as E3 ubiquitin-protein ligase XIAP) is a human protein-coding gene encoding an e3 ubiquitin-protein ligase protein. It directly restrains caspases and also participates in innate immune signaling, thereby controlling apoptosis and inflammatory responses. Loss-of-function variants cause X-linked lymphoproliferative syndrome type 2, with hemophagocytic lymphohistiocytosis, inflammatory bowel disease, and recurrent hyperinflammation. This analysis covers 845 XIAP variants and mutations. Of these, 67% have computational variant effect predictions. Disease context includes X-linked lymphoproliferative disease, neurodegenerative disease, and inflammatory bowel disease. Example XIAP variants include M1?, T2A, and F3*.
Variant analysis overview
- Gene: XIAP
- Protein: E3 ubiquitin-protein ligase XIAP
- UniProt accession: P98170
- Organism: Homo sapiens
- Variants analyzed: 845
- Variant scope: all variants
- Completed: 2026-08-21
Variant and mutation evidence
- Variant composition: 525 unspecified-consequence records; 7 frameshift variants; 120 synonymous variants; 176 missense variants; 5 in-frame deletions; 8 stop-gained variants; 4 splice-region variants
- Prediction scores: 569 variants have prediction scores (67% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: X-linked lymphoproliferative disease, neurodegenerative disease, inflammatory bowel disease, hereditary disease, Splenomegaly, Sepsis, X-linked sideroblastic anemia 1, Recurrent infections, lymphoproliferative syndrome 2, autoinflammatory syndrome, neoplasm, cancer.
Protein structure and variant hotspots
- Protein features: 4 binding sites; 1 post-translational modification sites.
- PTM context: 2 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable XIAP variants
Examples include M1?, T2A, F3*, F3F, S5G, S5N, S5S, F6L. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV6302, cosmic curated COSV63024, cosmic curated COSV10467, Variant assessed as somatic; high impact.
- T2A (p.Thr2Ala), rs2053344360, ClinGen CA414122484, ClinVar RCV002884698, TOPMed rs2053344360, REVEL 0.12, CADD 22.80, Uncertain significance, Inborn genetic diseases
- F3* (p.Phe3Ter), gnomAD X-123885667-CTT-C, CADD 25.00
- F3F (p.Phe3Phe), rs1259522787, gnomAD X-123885671-T-C, CADD 10.30
- S5G (p.Ser5Gly), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- S5N (p.Ser5Asn), Ensembl rs2053344451, REVEL 0.07, CADD 16.30
- S5S (p.Ser5Ser), rs1424970288, gnomAD X-123885677-T-C, CADD 12.20
- F6L (p.Phe6Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- F6F (p.Phe6Phe), rs2053344531, gnomAD X-123885680-T-C, CADD 11.70
- G8E (p.Gly8Glu), rs140889955, ClinGen CA10507986, ClinVar RCV001512709, 1000Genomes rs140889955, REVEL 0.02, CADD 10.50, Benign, X-linked lymphoproliferative disease due to XIAP deficiency
- G8R (p.Gly8Arg), cosmic curated COSV63022
- S9Y (p.Ser9Tyr), NCI-TCGA Cosmic COSV6302, cosmic curated COSV63022, Variant assessed as somatic; moderate impact.
- K10E (p.Lys10Glu), ExAC rs778934547
- K10N (p.Lys10Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K10Q (p.Lys10Gln), gnomAD X-123885690-A-C, REVEL 0.09, CADD 20.20
- T11S (p.Thr11Ser), ExAC rs748327341, gnomAD rs748327341, REVEL 0.09, CADD 17.10
- T11P (p.Thr11Pro), gnomAD X-123885693-A-C, REVEL 0.11, CADD 16.60
- T11T (p.Thr11Thr), gnomAD X-123885695-T-C, CADD 11.40
- C12W (p.Cys12Trp), Ensembl rs1377391891
- C12Y (p.Cys12Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- C12S (p.Cys12Ser), gnomAD X-123885697-G-C, REVEL 0.07, CADD 15.40
- P14T (p.Pro14Thr), Ensembl rs2148089294, REVEL 0.08, CADD 13.80
- P14S (p.Pro14Ser), gnomAD X-123885702-C-T, REVEL 0.08, CADD 15.90
- P14H (p.Pro14His), gnomAD X-123885703-C-A, REVEL 0.06, CADD 23.70
- A15T (p.Ala15Thr), cosmic curated COSV63022, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- A15A (p.Ala15Ala), rs2053344730, gnomAD X-123885707-A-G, CADD 13.20
- D16Y (p.Asp16Tyr), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D16D (p.Asp16Asp), gnomAD X-123885710-C-T, CADD 10.30
- I17M (p.Ile17Met), NCI-TCGA TCGA novel, REVEL 0.09, CADD 17.30, Variant assessed as somatic; moderate impact.
- I17V (p.Ile17Val), gnomAD X-123885711-A-G, REVEL 0.04, CADD 15.20
- N18S (p.Asn18Ser), gnomAD X-123885715-A-G, REVEL 0.10, CADD 14.90
- K19M (p.Lys19Met), Ensembl rs2053344810, REVEL 0.15, CADD 19.10
- K19R (p.Lys19Arg), gnomAD X-123885716-TA-T, CADD 23.10
- E20* (p.Glu20Ter), cosmic curated COSV10527
- E20G (p.Glu20Gly), gnomAD rs1419364869, REVEL 0.08, CADD 22.50
- E21D (p.Glu21Asp), cosmic curated COSV10817, REVEL 0.08, CADD 19.20
- E21K (p.Glu21Lys), rs770762804, ClinGen CA10507989, ClinVar RCV003623950, ExAC rs770762804, REVEL 0.06, CADD 22.40, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- E22* (p.Glu22Ter), NCI-TCGA Cosmic COSV6302, cosmic curated COSV63022, Variant assessed as somatic; high impact.
- F23L (p.Phe23Leu), cosmic curated COSV63024
- F23S (p.Phe23Ser), gnomAD X-123885730-T-C, REVEL 0.30, CADD 25.80
- V24A (p.Val24Ala), NCI-TCGA Cosmic COSV6302, Variant assessed as somatic; moderate impact.
- V24E (p.Val24Glu), cosmic curated COSV63023
- V24* (p.Val24Ter), rs755619494, gnomAD X-123885731-TG-T, CADD 23.70
- V24I (p.Val24Ile), gnomAD X-123885732-G-A, REVEL 0.04, CADD 15.00
- V24V (p.Val24Val), rs1209504379, gnomAD X-123885734-A-G, CADD 10.90
- E25K (p.Glu25Lys), cosmic curated COSV63023
- E25Q (p.Glu25Gln), rs781204574, ClinGen CA10507991, cosmic curated COSV63022, ClinVar RCV000640876, REVEL 0.09, CADD 19.70, Conflicting interpretations, Inborn genetic diseases; X-linked lymphoproliferative disease due to XIAP defici
- E26* (p.Glu26Ter), cosmic curated COSV63023
- E26G (p.Glu26Gly), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10084, Variant assessed as somatic; moderate impact.
- F27L (p.Phe27Leu), ExAC rs745585920, gnomAD rs745585920, REVEL 0.06, CADD 12.60
- N28K (p.Asn28Lys), rs2522584297, ClinGen CA414122674, ClinVar RCV003263231, Uncertain significance, Inborn genetic diseases
- R29I (p.Arg29Ile), NCI-TCGA Cosmic COSV1008, NCI-TCGA Cosmic COSV6302, cosmic curated COSV63021, Variant assessed as somatic; moderate impact.
- R29T (p.Arg29Thr), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10084, NCI-TCGA Cosmic COSV6302, Variant assessed as somatic; moderate impact.
- L30F (p.Leu30Phe), cosmic curated COSV10084
- K31K (p.Lys31Lys), gnomAD X-123885755-A-G, CADD 9.59
- T32N (p.Thr32Asn), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- T32P (p.Thr32Pro), gnomAD X-123885756-A-C, REVEL 0.84, CADD 25.00
- F33L (p.Phe33Leu), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10084, gnomAD rs1467313254, REVEL 0.94, CADD 24.20, Variant assessed as somatic; moderate impact.
- F33S (p.Phe33Ser), gnomAD X-123885760-T-C, REVEL 0.94, CADD 27.00
- A34S (p.Ala34Ser), NCI-TCGA Cosmic COSV1008, cosmic curated COSV10084, Variant assessed as somatic; moderate impact.
- A34V (p.Ala34Val), gnomAD rs1300855425, REVEL 0.11, CADD 18.20
- N35D (p.Asn35Asp), cosmic curated COSV63024
- N35S (p.Asn35Ser), rs769664549, ClinGen CA10507993, ClinVar RCV003513322, ExAC rs769664549, REVEL 0.21, CADD 16.00, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- P37S (p.Pro37Ser), cosmic curated COSV10527
- S38C (p.Ser38Cys), cosmic curated COSV10467
- G39A (p.Gly39Ala), gnomAD rs1313608508, REVEL 0.05, CADD 12.80
- G39C (p.Gly39Cys), rs775237858, ClinGen CA10507994, ClinVar RCV000918693, ClinVar RCV005423091, REVEL 0.23, CADD 18.10, Conflicting interpretations, not provided; X-linked lymphoproliferative disease due to XIAP deficiency
- G39D (p.Gly39Asp), cosmic curated COSV63024
- S40I (p.Ser40Ile), gnomAD rs1395494691, REVEL 0.32, CADD 25.10
- S40N (p.Ser40Asn), gnomAD X-123885781-G-A, REVEL 0.17, CADD 23.00
- P41A (p.Pro41Ala), gnomAD X-123885783-C-G, REVEL 0.40, CADD 22.60
- P41H (p.Pro41His), gnomAD X-123885784-C-A, REVEL 0.50, CADD 23.30
- V42I (p.Val42Ile), rs1236823622, ClinGen CA414122765, ClinVar RCV003625376, TOPMed rs1236823622, REVEL 0.07, CADD 20.00, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- V42L (p.Val42Leu), cosmic curated COSV10968
- A44T (p.Ala44Thr), cosmic curated COSV10744
- S45L (p.Ser45Leu), rs768460056, ClinGen CA10507996, ClinVar RCV003074535, ExAC rs768460056, REVEL 0.16, CADD 22.30, Benign, X-linked lymphoproliferative disease due to XIAP deficiency
- T46A (p.Thr46Ala), ExAC rs773990585, gnomAD rs773990585, REVEL 0.11, CADD 14.60
- T46S (p.Thr46Ser), ExAC rs773990585, gnomAD rs773990585, REVEL 0.21, CADD 19.40
- T46T (p.Thr46Thr), gnomAD X-123885800-A-C, CADD 2.38
- L47P (p.Leu47Pro), rs2522584443, ClinGen CA414122795, ClinVar RCV003625371, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- A48V (p.Ala48Val), TOPMed rs2053345657, gnomAD rs2053345657, REVEL 0.81, CADD 27.20
- R49* (p.Arg49Ter), rs2522584464, ClinGen CA414122804, ClinVar RCV003066377, Pathogenic
- R49L (p.Arg49Leu), NCI-TCGA TCGA novel, REVEL 0.56, CADD 25.80, Variant assessed as somatic; moderate impact.
- R49Q (p.Arg49Gln), rs770122195, ClinGen CA10507999, ClinVar RCV001509716, ClinVar RCV004793507, REVEL 0.42, CADD 23.70, Conflicting interpretations, not provided; X-linked lymphoproliferative disease due to XIAP deficiency
- F52S (p.Phe52Ser), cosmic curated COSV63022
- F52F (p.Phe52Phe), rs750942377, gnomAD X-123885818-T-C, CADD 12.60
- L53I (p.Leu53Ile), NCI-TCGA Cosmic COSV6302, cosmic curated COSV63022, Variant assessed as somatic; moderate impact.
- L53L (p.Leu53Leu), gnomAD X-123885821-T-C, CADD 2.15
- Y54H (p.Tyr54His), gnomAD X-123885822-T-C, REVEL 0.68, CADD 25.10
- T55I (p.Thr55Ile), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G56D (p.Gly56Asp), gnomAD rs1241696710, REVEL 0.85, CADD 25.90
- G56S (p.Gly56Ser), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- G56G (p.Gly56Gly), rs1602544077, gnomAD X-123885830-T-C, CADD 11.80
- G58E (p.Gly58Glu), TOPMed rs1198924317
- D59N (p.Asp59Asn), gnomAD X-123885837-G-A, REVEL 0.77, CADD 26.20
- T60T (p.Thr60Thr), rs370447539, gnomAD X-123885842-C-T, CADD 1.39
- V61L (p.Val61Leu), 1000Genomes rs2148089430, REVEL 0.73, CADD 25.10, Uncertain significance
- V61M (p.Val61Met), rs2148089430, ClinGen CA414122881, NCI-TCGA Cosmic COSV1008, cosmic curated COSV10084, REVEL 0.77, CADD 25.60, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- V61A (p.Val61Ala), gnomAD X-123885844-T-C, REVEL 0.77, CADD 25.40
- V61V (p.Val61Val), rs144938731, gnomAD X-123885845-G-T, CADD 7.02
- R62Q (p.Arg62Gln), rs755189208, ClinGen CA10508004, NCI-TCGA Cosmic COSV6302, cosmic curated COSV63023, REVEL 0.16, CADD 16.00, Uncertain significance, XIAP-related disorder; X-linked lymphoproliferative disease due to XIAP deficien
- R62W (p.Arg62Trp), rs147946593, ClinGen CA10508003, NCI-TCGA Cosmic COSV6302, cosmic curated COSV63023, REVEL 0.49, CADD 25.00, Uncertain significance, not provided; Inborn genetic diseases
- C63Y (p.Cys63Tyr), gnomAD X-123885850-G-A, REVEL 0.98, CADD 26.30
- F64L (p.Phe64Leu), NCI-TCGA Cosmic COSV6302, cosmic curated COSV63022, Variant assessed as somatic; moderate impact.
- F64S (p.Phe64Ser), gnomAD X-123885853-T-C, REVEL 0.86, CADD 27.50
- S65N (p.Ser65Asn), cosmic curated COSV10650
- C66Y (p.Cys66Tyr), rs2148089447, ClinGen CA414122917, ClinVar RCV001532709, Ensembl rs2148089447, AlphaMissense 0.99, MetaLR 0.92, Uncertain significance, not provided
- H67R (p.His67Arg), gnomAD rs1259044216, REVEL 0.33, CADD 13.90
- H67Y (p.His67Tyr), NCI-TCGA Cosmic COSV6302, cosmic curated COSV63022, Variant assessed as somatic; moderate impact.
- A68V (p.Ala68Val), rs2148089461, ClinGen CA414122935, ClinVar RCV001760757, ClinVar RCV002032872, REVEL 0.15, CADD 15.40, Uncertain significance, not provided; X-linked lymphoproliferative disease due to XIAP deficiency
- A68A (p.Ala68Ala), rs1373121118, gnomAD X-123885866-A-G, CADD 7.23
- A69V (p.Ala69Val), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V70G (p.Val70Gly), rs2522584640, ClinGen CA414122946, ClinVar RCV003625202, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- R72K (p.Arg72Lys), cosmic curated COSV10527, ESP rs141965442, ExAC rs141965442
- W73* (p.Trp73Ter), rs2053346219, ClinGen CA916081272, ClinVar RCV001065914, Ensembl rs2053346219, Pathogenic
- W73L (p.Trp73Leu), cosmic curated COSV10084
- G76* (p.Gly76Ter), cosmic curated COSV10527
- G76A (p.Gly76Ala), rs1481750191, ClinGen CA414122990, ClinVar RCV001210190, ClinVar RCV005298727, REVEL 0.66, CADD 25.10, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency; Inborn genetic dise
- G76E (p.Gly76Glu), cosmic curated COSV63021, REVEL 0.51, CADD 25.40
- G76V (p.Gly76Val), cosmic curated COSV10527
- G76G (p.Gly76Gly), gnomAD X-123885890-A-G, CADD 12.30
- D77E (p.Asp77Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- D77N (p.Asp77Asn), TOPMed rs954289858, REVEL 0.76, CADD 27.00
- S78* (p.Ser78Ter), cosmic curated COSV63021
- S78S (p.Ser78Ser), gnomAD X-123885896-A-C, CADD 8.79
- A79T (p.Ala79Thr), TOPMed rs2053346523, REVEL 0.52, CADD 25.60, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- A79E (p.Ala79Glu), gnomAD X-123885898-C-A, REVEL 0.62, CADD 25.00
- V80A (p.Val80Ala), gnomAD X-123885901-T-C, REVEL 0.24, CADD 22.30
- G81R (p.Gly81Arg), gnomAD X-123885903-G-A, REVEL 0.33, CADD 26.00
- G81E (p.Gly81Glu), gnomAD X-123885904-G-A, REVEL 0.13, CADD 18.50
- H83Q (p.His83Gln), NCI-TCGA Cosmic COSV6302, cosmic curated COSV63022, Variant assessed as somatic; moderate impact.
- H83R (p.His83Arg), Ensembl rs111626628
- R84S (p.Arg84Ser), cosmic curated COSV10084
- R84T (p.Arg84Thr), rs2522584748, ClinGen CA414123041, ClinVar RCV003512316, REVEL 0.48, CADD 24.80, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- K85N (p.Lys85Asn), ExAC rs758511888, gnomAD rs758511888, REVEL 0.16, CADD 17.90
- V86L (p.Val86Leu), gnomAD X-123885918-G-T, REVEL 0.09, CADD 12.70
- P88Q (p.Pro88Gln), cosmic curated COSV63021
- N89H (p.Asn89His), ESP rs142087897, TOPMed rs142087897, REVEL 0.37, CADD 24.10
- N89K (p.Asn89Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N89D (p.Asn89Asp), gnomAD X-123885927-A-G, REVEL 0.20, CADD 21.00
- C90* (p.Cys90Ter), NCI-TCGA Cosmic COSV6302, cosmic curated COSV63021, Variant assessed as somatic; high impact.
- C90Y (p.Cys90Tyr), cosmic curated COSV63024
- R91* (p.Arg91Ter), cosmic curated COSV63021
- R91G (p.Arg91Gly), rs2053346722, ClinGen CA414123085, ClinVar RCV001206134, Ensembl rs2053346722, AlphaMissense 0.11, MetaLR 0.21, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- R91I (p.Arg91Ile), cosmic curated COSV63022
- R91K (p.Arg91Lys), rs1330516966, ClinGen CA414123087, ClinVar RCV001219664, ClinVar RCV006387211, REVEL 0.11, CADD 14.70, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency; Inborn genetic dise
- F92F (p.Phe92Phe), rs45575532, gnomAD X-123885938-T-C, CADD 12.50
- N94S (p.Asn94Ser), gnomAD X-123885943-A-G, REVEL 0.08, CADD 15.90
- N94N (p.Asn94Asn), rs1173739392, gnomAD X-123885944-C-T, CADD 6.50
- G95S (p.Gly95Ser), rs745844064, ClinGen CA10508009, ClinVar RCV002191175, ExAC rs745844064, REVEL 0.17, CADD 22.80, Likely benign, X-linked lymphoproliferative disease due to XIAP deficiency
- G95D (p.Gly95Asp), gnomAD X-123885946-G-A, REVEL 0.16, CADD 20.30
- G95G (p.Gly95Gly), rs1435284179, gnomAD X-123885947-C-G, CADD 9.26
- Y97H (p.Tyr97His), gnomAD rs1175389780, REVEL 0.04, CADD 16.40
- Y97F (p.Tyr97Phe), gnomAD X-123885952-A-T, REVEL 0.09, CADD 17.70
- L98L (p.Leu98Leu), gnomAD X-123885956-T-G, CADD 6.45
- E99G (p.Glu99Gly), rs769904534, ClinGen CA10508010, ClinVar RCV002173698, ClinVar RCV003438958, REVEL 0.12, CADD 22.00, Conflicting interpretations, not provided; X-linked lymphoproliferative disease due to XIAP deficiency
- E99K (p.Glu99Lys), cosmic curated COSV63021, TOPMed rs1174668840
- N100D (p.Asn100Asp), TOPMed rs1379036403, gnomAD rs1379036403, REVEL 0.09, CADD 19.80, Uncertain significance, X-linked lymphoproliferative disease due to XIAP deficiency
- N100N (p.Asn100Asn), rs2148089584, gnomAD X-123885962-T-C, CADD 5.34
- S101G (p.Ser101Gly), ESP rs374922007, ExAC rs374922007, TOPMed rs374922007, gnomAD rs374922007
- S101I (p.Ser101Ile), NCI-TCGA Cosmic COSV6302, cosmic curated COSV63022, Variant assessed as somatic; moderate impact.
- A102V (p.Ala102Val), cosmic curated COSV10817
- T103M (p.Thr103Met), rs749157868, ClinGen CA10508012, cosmic curated COSV63023, ClinVar RCV001510246, REVEL 0.02, CADD 5.16, Conflicting interpretations, Inborn genetic diseases; not provided; X-linked lymphoproliferative disease due
- T103A (p.Thr103Ala), gnomAD X-123885969-A-G, REVEL 0.01, CADD 1.81
- T103T (p.Thr103Thr), rs140230812, gnomAD X-123885971-G-A, CADD 0.80
- Q104H (p.Gln104His), TOPMed rs2053347328
- S105C (p.Ser105Cys), gnomAD X-123885976-C-G, REVEL 0.03, CADD 19.30
- N107I (p.Asn107Ile), Ensembl rs28382721, REVEL 0.09, CADD 17.50, Uncertain significance
- N107S (p.Asn107Ser), rs28382721, ClinGen CA335076264, ClinVar RCV001342388, ClinVar RCV004692598, REVEL 0.08, CADD 15.70, Uncertain significance, not provided; X-linked lymphoproliferative disease due to XIAP deficiency
- N107D (p.Asn107Asp), gnomAD X-123885981-A-G, REVEL 0.02, CADD 15.70
- S108C (p.Ser108Cys), Ensembl rs2053347432
- G109S (p.Gly109Ser), gnomAD X-123885987-G-A, REVEL 0.03, CADD 10.50
- G109V (p.Gly109Val), gnomAD X-123885988-G-T, REVEL 0.03, CADD 9.74
- G109D (p.Gly109Asp), gnomAD X-123885988-G-A, REVEL 0.04, CADD 13.50
- G109G (p.Gly109Gly), rs774062590, gnomAD X-123885989-T-C, CADD 10.80
- I110I (p.Ile110Ile), rs1301732218, gnomAD X-123885992-C-A, CADD 8.73
- Q111* (p.Gln111Ter), cosmic curated COSV10943
- N112H (p.Asn112His), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N112S (p.Asn112Ser), cosmic curated COSV10084, REVEL 0.06, CADD 17.40
- N112T (p.Asn112Thr), gnomAD X-123885997-A-C, REVEL 0.10, CADD 22.60
Public XIAP analysis runs
- XIAP analysis run — XIAP (845 variants) — completed 2026-08-21